Source comparison
SS-31 Dosage Guide: Administration Method Comparison
The table below compares dosage ranges, pharmacokinetic profiles, and research applications across the three viable administration routes for SS-31 in preclinical models. Subcutaneous 1-5mg/kg 60-90 minutes 5-7 hours Gradual, sustained Chronic heart failure, a
This comparison does not assign a generated winner or score.
- The table below compares dosage ranges, pharmacokinetic profiles, and research applications across the three viable administration routes for SS-31 in preclinical models.
- Subcutaneous
- 1-5mg/kg
- 60-90 minutes
- 5-7 hours
- Gradual, sustained
- Chronic heart failure, aging, metabolic dysfunction, long-term neuroprotection
- Preferred for studies >7 days; consistent tissue levels with minimal stress
- Intravenous
- 2.5-10mg/kg
- 5-10 minutes
- 3-4 hours
- Rapid but transient
- Ischemia-reperfusion, acute organ injury, sepsis, stroke
- Required for acute intervention; narrow therapeutic window
- Intraperitoneal
- 3-10mg/kg
- 20-30 minutes
- 4-6 hours
- Moderate
- Pilot studies, mitochondrial myopathy, models where IV is prohibitive
- Middle-ground option; less predictable than SC or IV but technically simpler
- Subcutaneous administration offers the best balance of efficacy, reproducibility, and animal welfare for the majority of research applications. Intravenous is indispensable for acute injury models but introduces technical variability and stress that can confound metabolic and behavioral endpoints. Intraperitoneal dosing is useful when SC absorption is too slow and IV access is impractical, though dose optimization may be required due to variable bioavailability.